Paper Review Records
All Paper Review Records
20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
373
days
Trials in progress: CARMAN – study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance
Authors
Marie-Kristin Tilch; Christian Schmidt; Marek Trneny; Eva Giné; Olivier Hermine; Anke Ohler; Stephanie Herold; Eva Hoster; Linmiao Jiang; Christiane Pott; Martin Dreyling; Georg HessShow moreShow less
Affiliations
1. Department of Hematology and Medical Oncology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany; 2. Department of Internal Medicine III, University Hospital, Ludwig Maximilian University (LMU) Munich, LMU Medizin, Munich, Germany; 3. First Department of Internal Medicine -Hematology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic; 4. Department of Hematology, Hospital Clínic of Barcelona, IDIBAPS, Barcelona, Spain; 5. CEREMAST Necker Hospital, Paris, France; 6. Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), LMU Medizin, LMU Munich, Munich, Germany; 7. Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, GermanyShow moreShow less
35
days
DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all- trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy
Authors
Olga Grishina; Claudia Schmoor; Caroline Sellner; Björn Hackanson; Jan-Henrik Mikesch; Iordanis Deligiannis; Felicitas Thol; Martina Crysandt; Christian Junghanss; Volker Runde; Paul La Rosée; Lino Lars Teichmann; Haifa Kathrin Al-Ali; Tim Sauer; Ulrich Germing; Frank Griesinger; Stefan Lukic; Jürgen Krauter; Snjezana Janjetovic; Jan Koch; Peter Staib; Julian Topaly; Maike de Wit; Doris Maria Kraemer; Lorenz Oelschläger; Ulf Schnetzke; Oliver Schmah; Swen Wessendorf; Cyrus Khandanpour; Lukas Kündgen; Monika Schwalenberg; Michael Heuser; Arnold Ganser; Hartmut Döhner; Ralph Wäsch; Michael LübbertShow moreShow less
Affiliations
1. Clinical Trials Unit, Medical Center – University of Freiburg, Faculty of Medicine - University of Freiburg, Freiburg, Germany; 2. Department of Hematology/Oncology, Comprehensive Cancer Center Augsburg as Part of the CCC-WERA Consortium, University Medical Center Augsburg, Augsburg, Germany; 3. Department of Medicine A, University Hospital Münster, Münster, Germany; 4. Internal Medicine I, Brothers Hospital Trier, Trier, Germany; 5. Department of Hematology, Hemostasis, Oncology, and Cell Therapy, Hannover Medical School, Hannover, Germany; 6. Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, University Hospital Aachen, Aachen, Germany; 7. Department of Internal Medicine, Clinic for Hematology, Stem Cell Therapy and Palliative Medicine, Rostock University Medical Center, Hemostasis, Rostock, Germany; 8. Department of Hematology, Oncology and Palliative Care, Wilhelm-Anton- Hospital, Goch, Germany; 9. Department for Internal Medicine II, Schwarzwald‐Baar Klinikum, Villingen-Schwenningen, Germany; 10. Department of Medicine III, University Hospital Bonn, Bonn, Germany; 11. Krukenberg Cancer Center Halle, Medical Faculty, Martin-Luther- University Halle-Wittenberg, Halle (Saale), Germany; 12. Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany; 13. Department of Hematology, Oncology, and Clinical Immunology, Heinrich- Heine University Düsseldorf, Düsseldorf, Germany; 14. Clinic for Hematology and Oncology, Pius-Hospital Oldenburg, University Medicine Oldenburg, Oldenburg, Germany; 15. Department of Hematology and Oncology, Augusta-Kranken-Anstalt, Academic Teaching Hospital of the Ruhr-University Bochum, Bochum, Germany; 16. Department of Hematology and Oncology, Municipal Hospital Braunschweig, Braunschweig, Germany; 17. Department of Hematology and Cell Therapy, Helios Klinikum Berlin- Buch, Berlin, Germany; 18. University Medical Center Mannheim (UMM), Mannheim, Germany; 19. Department of Hematology and Oncology, St Antonius Hospital Eschweiler, Eschweiler, Germany; 20. Department of Hematology and Oncology, CaritasKlinikum Saarbrücken, Saarbrücken, Germany; 21. Department of Internal Medicine, Hematology, Oncology and Palliative Medicine, Vivantes Klinikum Neukölln, Berlin, Germany; 22. St. Josefs-Hospital Hagen, Hagen, Germany; 23. Department of Hematology and Oncology, Schleswig-Holstein, University Medical Center, University Cancer Center Schleswig-Holstein, Lübeck, Germany; 24. Department of Hematology and Medical Oncology, Clinic for Internal Medicine II, Comprehensive Cancer Center Central Germany-Campus Jena, University Hospital Jena, Jena, Germany; 25. Section of Hematology and Oncology, Ortenau Medical Care Center, Ortenau Klinikum Lahr, Lahr, Germany; 26. Department of Hematology and Oncology, Klinikum Esslingen, Esslingen, Germany; 27. University Clinic for Internal Medicine – Oncology and Hematology, Oldenburg Medical Center, University of Oldenburg, Oldenburg, Germany; 28. Department of Hematology, Oncology, Infectious Diseases and Palliative Care, Municipal Hospital Karlsruhe, Karlsruhe, Germany; 29. Department of Hematology, Oncology and Palliative Care, Hospital Lüdenscheid, Lüdenscheid, Germany; 30. Department of Internal Medicine IV, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany; 31. Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany; 32. Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center – University of Freiburg, Faculty of Medicine - University of Freiburg, Freiburg, GermanyShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days